GlassScriptPhysician profile
Phillip J Koo
NPI 1306902259
$242,972.52
in general payments reported to CMS, 2019-2025
22 companies · $27K in 2025
The $27K reported for 2025 was more than what 98% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $22K · 2021: $19K · 2022: $34K · 2023: $28K · 2024: $74K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $85K · Travel and Lodging: $28K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,055 · Food and Beverage: $5,310 · Honoraria: $4,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $84,873.25 |
| Travel and Lodging | $27,838.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,055.00 |
| Food and Beverage | $5,310.37 |
| Honoraria | $4,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42,119.79 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $33,681.65 | 2019-2023 | Lynparza |
| Siemens Medical Solutions USA, INC. | $29,102.36 | 2024 | Biograph Horizon-3r, Biograph Vision 600 (8 Ring/64 Ct) |
| Novartis Pharmaceuticals Corporation | $20,609.66 | 2021-2025 | |
| Progenics Pharmaceuticals, INC. | $19,468.54 | 2020-2024 | Pylarify |
| Advanced Accelerator Applications | $19,158.92 | 2020-2022 | |
| Blue Earth Diagnostics | $18,758.59 | 2019-2025 | Posluma |
| Bayer Healthcare LLC | $13,221.11 | 2024-2025 | |
| Astellas Pharma US INC | $10,961.62 | 2019-2024 | Xtandi |
| Janssen Scientific Affairs, LLC | $5,844.76 | 2019-2024 | Erleada |
| Astellas Pharma Global Development | $4,624.00 | 2022-2024 | Xtandi |
| Astrazeneca Pharmaceuticals LP | $4,622.63 | 2019-2024 | Lynparza |
| Cardinal Health 414 LLC | $4,550.00 | 2024 | |
| Astrazeneca Uk Limited | $3,993.09 | 2025 | Lynparza |
| Telix Pharmaceuticals | $3,354.20 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,144.00 | 2023 | |
| Ge Healthcare | $2,400.00 | 2023-2025 | |
| Curium US LLC | $1,860.93 | 2023-2025 | Detectnet |
| Pfizer INC. | $772.44 | 2019-2025 | |
| Cardinal Health 200 LLC | $375.00 | 2024 | |
| Janssen Biotech, INC. | $182.44 | 2019-2023 | Erleada |
| Voximetry, INC. | $166.79 | 2023 | Torch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Koo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.